FIRST DRAFT OF THE RETROSPECTIVE STUDY回顾性研究的第一稿.pptVIP

FIRST DRAFT OF THE RETROSPECTIVE STUDY RETROSPECTIVE STUDY AIM: To evaluate the presence of the markers required for the new ESPGHAN protocol in 50 unselected consecutive patients in each country 10 countries: Albania, Bosnia H, Croatia, France, Greece, Italy (Naples), Italy (Sicily), Morocco, Slovenia, Turkey ESPECTED RESULTS: To estimate the percentage of patients who bear the markers required by the new approach To produce a quite original picture of the CD diagnosis in the area DATA REQUIRED Date of birth Date of diagnosis Sex Biopsy results Anti TGase (UI) HLA genotype 3 symptoms Familiarity Associated disease Treatment AGE AT DIAGNOSIS AGE AT DIAGNOSIS/COUNTRY FAMILIARITY ASSOCIATED DISEASES SYMPTOMS LIMITATIONS Selection bias Bad management of the missing data: Uncompleted files Anti TGase: Meaning of the NEGATIVE results Lack of standardization Biopsy: Lack of standardization LIMITATIONS FUTURE PROSPECTS Prospective study for 6 months (50 cases/country) to evaluate the applicability of the new ESPGHAN protocol A positive evaluation of the new protocol could reduce the confinement of the diagnosis to specialized centres only * Workshop MEDICEL The Mediterranean Network for Celiac Disease III Progress Meeting PastaTrend, BolognaFiere Bologna, April 5th 2011 498 cases F:M = 2:1 35,5% 64,5% SEX 46,5% 32% 16,6% 4,9% 0-4 y 5-9 y 10-14 y 15-22 y 0-4 y 5-9 y 10-14 y 15-22 y 74% 6,7% 16,3% 2,8% 64,4% NOT Genotyped 28,2% 30,6% 17,7% 23,4% 74,3 370 NO Familiarity 25,7 128 Familiarity Percent % Frequency 11,4% 2,4% 1,8% 4,8% 0,6% 1,6% 0,4% 3,6% 73,3% No associated diseases ONLY 22 ASYMPTOMATICS It is a SYMPTOMATIC CD No differences between Males and Females BIOPSY RESULTS NOT DONE = 7,6% 3% 4,3% 7% 14,3% 23,7% 45,7% ANTI-TGASE LEVELS AND BIOPSY NO Atrophy Atrophy ANTI-TGASE LEVELS AND BIOPSY 50 UI 50-100 UI 100 UI THANK YOU * * * * *